About ASCAT
Discover the latest breakthroughs in haemoglobinopathies at this ground-breaking event. Whether you're a healthcare professional, researcher, or someone affected by these conditions, the ASCAT Conference offers a unique opportunity to stay informed.
Explore new advancements in diagnosis, treatment, and emerging therapies for Sickle Cell Disease and Thalassemia. Engage in insightful discussions, witness cutting-edge research presentations, and network with peers to contribute to the continuous evolution of this field.
Selected abstracts will be featured in HemaSphere (EHA) journals, ensuring widespread dissemination of vital discoveries. Additionally, earn CPD and CME credits to enhance your professional growth. Join us at ASCAT and be part of the progress in haemoglobinopathies.
ASCAT CONFERENCE 2024
This year in collaboration with European Hematology Association & British Society for Haematology, ASCAT brings to you:
Welcome to the 19th Annual Scientific ASCAT Conference
For the fifth consecutive year, ASCAT proudly collaborates with the European Hematology Association (EHA) and the British Society of Haematology (BSH) for a ground-breaking event supported by Eurobloodnet (EBN) and various patient groups.
Join us at the historic County Hall London, overlooking the Houses of Parliament and 'Big Ben,' providing an inspiring backdrop for academic presentations and networking.
Our Focus
In alignment with the overarching goal of our conference, which focuses on "Improving the lives of those living with Sickle Cell Disease & Thalassaemia," our discussions highlight the pressing need for collective action to address these conditions. Despite the development of new therapies, including gene therapies, it's crucial to recognize that systemic inequities persist in accessing these advancements, particularly for marginalized communities.
As we convene to explore innovative approaches and insights, let us prioritize fostering collaboration among patient groups, medical professionals, researchers, policymakers, and affected communities to address these challenges.
Through this congress, our aim is to raise awareness, improve care accessibility, and drive transformative research initiatives, ultimately striving to ensure equitable support and an enhanced quality of life for all individuals impacted by these haemoglobinopathies.
Our Objectives
Equitable Action: Unite in addressing challenges faced by individuals with Sickle Cell Disease & Thalassaemia through collective commitment.
Innovation Focus: Explore and share innovative approaches to revolutionize the treatment and care of individuals with haemoglobinopathies.
Transformative Research: Inspire and support research initiatives for ground-breaking developments in understanding and treating haemoglobinopathies.
scientific program committee
Meet the esteemed members of the Scientific Program Committee, led by Professor Biree Andemariam, shaping the intellectual landscape of ASCAT 2024. Together, this diverse and accomplished group ensures the program's excellence, covering a spectrum of expertise to advance our understanding and treatment of Sickle Cell Disease and Thalassaemia.
